
Please try another search
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Zheng Tan | - | - | Executive Chairman |
Yuezhong Li | - | - | Non-Executive Director |
Sujiu Peng | 46 | 2020 | Independent Non-Executive Director |
Fan Yang | 44 | 2023 | Non-Executive Director |
Yingdian Wang | 63 | 2020 | Independent Non-Executive Director |
Ruihua Wang | 61 | 2023 | Non-Executive Director |
Xiaohui Yu | 47 | 2025 | Non-Executive Director |
Chi Kit Ng | 52 | 2020 | Independent Non-Executive Director |
Donghu Wang | 71 | 2023 | Non-Executive Director |
Xin Yang | 44 | 2025 | Non-Executive Director |
Guoguang Zhang | 45 | 2025 | Independent Non-Executive Director |
Rui Liu | 52 | 2025 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review